

## Optimizing Patient Outcomes in Bipolar Disorder: Long-term Management of Major Depressive Episodes - Tweetorial #4

### References

#### Tweet 4

Freeland KN, Cogdill BR, Ross CA, et al. Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting. *Am J Health Syst Pharm*. 2015;72(23 Suppl 3):S156-161. doi:10.2146/sp150023

Greene M, Paladini L, Lemmer T, Piedade A, Touya M, Clark O. Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA. *Neuropsychiatr Dis Treat*. 2018;14:1545-1559. doi:10.2147/NDT.S166730

#### Tweet 6

Boyce P, Irwin L, Morris G, et al. Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder-a critical review of the evidence. *Bipolar Disord*. 2018;20 Suppl 2:25-36. doi:10.1111/bdi.12698

#### Tweet 8

Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018;20(2):97-170. doi:10.1111/bdi.12609

#### Tweet 10

Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: a systematic review and network meta-analysis. *World J Biol Psychiatry*. 2018;19(8):586-601. doi:10.1080/15622975.2017.1285050

Stahl SM, Morrisette DA, Faedda G, et al. Guidelines for the recognition and management of mixed depression. *CNS Spectr*. 2017;22(2):203-219. doi:10.1017/S1092852917000165

#### Tweet 13

Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. *World J Biol Psychiatry*. 2018;19(8):586-601. doi:10.1080/15622975.2017.1285050

Stahl SM, Morrisette DA, Faedda G, et al. Guidelines for the recognition and management of mixed depression. *CNS Spectr*. 2017;22(2):203-219. doi:10.1017/S1092852917000165

#### Tweet 14

Yatham LN, Kennedy SH, Parikh S V., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018;20(2):97-170. doi:10.1111/bdi.12609

**Tweet 15**

Boyce P, Irwin L, Morris G, et al. Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder-A critical review of the evidence. *Bipolar Disord*. 2018;20 Suppl 2:25-36. doi:10.1111/bdi.12698

Chakrabarti S. Treatment alliance and adherence in bipolar disorder. *World J Psychiatry*. 2018;8(5):114-124. doi:10.5498/wjp.v8.i5.114

García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. *J Clin Psychopharmacol*. 2016;36(4):355-371. doi:10.1097/JCP.0000000000000523

## **Glossary**

AEs, adverse events

CANMAT, Canadian Network for Mood Anxiety Treatment

Esp, especially

Incl, including

ISBD, International Society for Bipolar Disorders

Lit, literature

OFC, olanzapine/fluoxetine combination

Pts, Patients

QOL, quality of life

Tx, treatment

w/, with

w/in, within

YO, year-old